Decision ruleSurgery
UCLA Integrated Staging System for renal cell carcinoma (UISS)
Classifies risk after nephrectomy by combining TNM stage, Fuhrman grade and ECOG performance status.
Updated 30 October 2026
When to use it
Patients with renal cell carcinoma after nephrectomy, for prognosis, follow-up planning and adjuvant trial selection.
What it needs
- T (1997 TNM)
- N (1997 TNM)
- Distant metastasis (M)
- Fuhrman nuclear grade
- ECOG performance status
The points for each answer and the automatic total are in the app.
How to interpret it
| Result | Interpretation |
|---|---|
| ≤ 1 | Localised disease: low risk |
| 2 | Localised disease: intermediate risk |
| 3 | Localised disease: high risk |
| 11 | Metastatic disease: low risk |
| 12 | Metastatic disease: intermediate risk |
| ≥ 13 | Metastatic disease: high risk |
Practical tip
It uses 1997 TNM, in which adrenal invasion was T3a; contiguous adrenal invasion is now T4.
3 more practical tips in the app.
Reference
- Zisman A, Pantuck AJ, Wieder J, et al. Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol. 2002;20(23):4559-4566.
- Zisman A, Pantuck AJ, Dorey F, et al. Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol. 2001;19(6):1649-1657.
- Patard JJ, Kim HL, Lam JS, et al. Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study. J Clin Oncol. 2004;22(16):3316-3322.
A support tool for healthcare professionals: it guides and does not replace clinical judgement.
